GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Net Income Including Noncontrolling Interests

Shanghai Henlius Biotech (HKSE:02696) Net Income Including Noncontrolling Interests : HK$331 Mil (TTM As of Jun. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Shanghai Henlius Biotech Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Shanghai Henlius Biotech's Net Income Including Noncontrolling Interests for the three months ended in Jun. 2024 was HK$0 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2024 was HK$331 Mil.

Shanghai Henlius Biotech Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Shanghai Henlius Biotech's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Henlius Biotech Net Income Including Noncontrolling Interests Chart

Shanghai Henlius Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial -974.17 -1,177.78 -1,204.94 -776.41 597.22

Shanghai Henlius Biotech Quarterly Data
Dec17 Mar18 Jun18 Dec18 Mar19 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -393.93 - 180.02 151.19 -

Shanghai Henlius Biotech Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$331 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Henlius Biotech Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Henlius Biotech Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Henlius Biotech Inc (HKSE:02696) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
HKSE:00775 HKSE:02157 HKSE:06855 HKSE:02480 HKSE:02105 HKSE:02487 HKSE:06955 HKSE:02171 HKSE:02315 HKSE:02179 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
B8 Building, No. 188 Yizhou Road, 11th Floor, Xuhui District, Shanghai, CHN, 200233
Website
https://www.henlius.com
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Executives
Qatar Investment Authority 2201 Interest of corporation controlled by you
Fosun Industrial Co., Limited 2101 Beneficial owner
Shanghai Fosun Pharmaceutical (group) Co., Ltd. 2201 Interest of corporation controlled by you
Fosun Holdings Limited 2201 Interest of corporation controlled by you
Fosun International Holdings Ltd. 2201 Interest of corporation controlled by you
Fosun International Limited 2201 Interest of corporation controlled by you
Guo Guangchang 2201 Interest of corporation controlled by you
Shanghai Fosun High Technology (group) Co., Ltd. 2201 Interest of corporation controlled by you
Liu Scott Shi-kau 2201 Interest of corporation controlled by you
Jiang Wei-dong 2201 Interest of corporation controlled by you
Henlius Biopharmaceuticals, Inc. 2101 Beneficial owner

Shanghai Henlius Biotech Headlines

No Headlines